LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 376

Search options

  1. Book ; Online ; E-Book: Orphan lung diseases

    Cottin, Vincent / Richeldi, Luca / Brown, Kevin / McCormack, Francis X.

    a clinical guide to rare lung disease

    2023  

    Author's details Vincent Cottin, Luca Richeldi, Kevin Brown, Francis X. McCormack editors
    Keywords Internal medicine ; Lung Diseases / physiopathology ; Rare Diseases / physiopathology
    Language English
    Size 1 Online-Ressource (xiii, 806 Seiten), Illustrationen
    Edition Second edition
    Publisher Springer
    Publishing place Cham
    Publishing country Switzerland
    Document type Book ; Online ; E-Book
    Remark Zugriff für angemeldete ZB MED-Nutzerinnen und -Nutzer
    HBZ-ID HT030016162
    ISBN 978-3-031-12950-6 ; 9783031129490 ; 3-031-12950-4 ; 3031129490
    DOI 10.1007/978-3-031-12950-6
    Database ZB MED Catalogue: Medicine, Health, Nutrition, Environment, Agriculture

    Full text online

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  2. Book: Orphan lung diseases

    Cottin, Vincent / Cordier, Jean-François / Richeldi, Luca

    a clinical guide to rare lung disease

    2015  

    Author's details Vincent Cottin ; Jean-Francois Cordier ; Luca Richeldi ed
    Keywords Lungs--Diseases--Diagnosis ; Lungs--Diseases--Treatment
    Subject code 616.24
    Language English
    Size XVIII, 625 S. : Ill., graph. Darst., 28 cm
    Edition 2015
    Publisher Springer
    Publishing place London u.a.
    Publishing country Great Britain
    Document type Book
    HBZ-ID HT018526315
    ISBN 978-1-4471-2400-9 ; 9781447124016 ; 1-4471-2400-6 ; 1447124014
    Database Catalogue ZB MED Medicine, Health

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Shelf markLoan statusLocation
    2015 A 433 available for loan (reading room) Lesesaal EG

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Experimental autotaxin inhibitors for the treatment of idiopathic pulmonary fibrosis.

    Simonetti, Jacopo / Ficili, Marco / Sgalla, Giacomo / Richeldi, Luca

    Expert opinion on investigational drugs

    2024  Volume 33, Issue 2, Page(s) 133–143

    Abstract: Introduction: Idiopathic Pulmonary Fibrosis (IPF) is a progressive, irreversible, and fatal lung disease with unmet medical needs. Autotaxin (ATX) is an extracellular enzyme involved in the generation of lysophosphatidic acid (LPA). Preclinical and ... ...

    Abstract Introduction: Idiopathic Pulmonary Fibrosis (IPF) is a progressive, irreversible, and fatal lung disease with unmet medical needs. Autotaxin (ATX) is an extracellular enzyme involved in the generation of lysophosphatidic acid (LPA). Preclinical and clinical data have suggested the ATX-LPAR signaling axis plays an important role in the pathogenesis and the progression of IPF.
    Areas covered: The aim of this review is to provide an update on the available evidence on autotaxin inhibitors in IPF and further details on the ongoing clinical studies involving these molecules.
    Expert opinion: The development of autotaxin inhibitors as a potential therapy for idiopathic pulmonary fibrosis has gained attention due to evidence of their involvement in the disease. Preclinical and early-phase clinical studies have explored these inhibitors' efficacy and safety, offering a novel approach in treating this disease. Combining autotaxin inhibitors with existing anti-fibrotic agents is considered for enhanced therapeutic effects. Large phase III trials assessed Ziritaxestat but yielded disappointing results, highlighting the importance of long-term observation and clinical outcomes in clinical research. Patient stratification and personalized medicine are crucial, as pulmonary fibrosis is a heterogeneous disease. Ongoing research and collaboration are essential for this advancement.
    MeSH term(s) Humans ; Idiopathic Pulmonary Fibrosis/drug therapy ; Precision Medicine ; Signal Transduction
    Language English
    Publishing date 2024-02-01
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 1182884-5
    ISSN 1744-7658 ; 0967-8298 ; 1354-3784
    ISSN (online) 1744-7658
    ISSN 0967-8298 ; 1354-3784
    DOI 10.1080/13543784.2024.2305126
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 3739: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Better be an Agnostic than a Believer (at Least in Pulmonary Fibrosis).

    Sgalla, Giacomo / Richeldi, Luca

    American journal of respiratory and critical care medicine

    2022  

    Language English
    Publishing date 2022-08-26
    Publishing country United States
    Document type Journal Article
    ZDB-ID 1180953-x
    ISSN 1535-4970 ; 0003-0805 ; 1073-449X
    ISSN (online) 1535-4970
    ISSN 0003-0805 ; 1073-449X
    DOI 10.1164/rccm.202207-1437ED
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Uh II Zs.80: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: Reply to Huang and Wei, Kang

    Sgalla, Giacomo / Richeldi, Luca

    American journal of respiratory and critical care medicine

    2022  Volume 206, Issue 7, Page(s) 919–920

    MeSH term(s) Drugs, Chinese Herbal ; Humans
    Chemical Substances Drugs, Chinese Herbal
    Language English
    Publishing date 2022-05-26
    Publishing country United States
    Document type Letter ; Comment
    ZDB-ID 1180953-x
    ISSN 1535-4970 ; 0003-0805 ; 1073-449X
    ISSN (online) 1535-4970
    ISSN 0003-0805 ; 1073-449X
    DOI 10.1164/rccm.202205-0850LE
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Uh II Zs.80: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: The Future of Clinical Trials in Idiopathic Pulmonary Fibrosis.

    Podolanczuk, Anna J / Richeldi, Luca / Martinez, Fernando J

    JAMA

    2023  Volume 329, Issue 18, Page(s) 1554–1555

    MeSH term(s) Humans ; Idiopathic Pulmonary Fibrosis/drug therapy ; Clinical Trials as Topic ; Forecasting
    Language English
    Publishing date 2023-05-09
    Publishing country United States
    Document type Editorial ; Comment
    ZDB-ID 2958-0
    ISSN 1538-3598 ; 0254-9077 ; 0002-9955 ; 0098-7484
    ISSN (online) 1538-3598
    ISSN 0254-9077 ; 0002-9955 ; 0098-7484
    DOI 10.1001/jama.2022.23955
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ua VI Zs.88: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article ; Online: BI 1015550: an investigational phosphodiesterase 4B (PDE4B) inhibitor for lung function decline in idiopathic pulmonary fibrosis (IPF).

    Sgalla, Giacomo / Simonetti, Jacopo / Cortese, Stefania / Richeldi, Luca

    Expert opinion on investigational drugs

    2023  Volume 32, Issue 1, Page(s) 17–23

    Abstract: Introduction: The two available therapies for idiopathic pulmonary fibrosis (IPF), pirfenidone and nintedanib, slow down but do not halt IPF progression. Therefore, several agents with specific molecular targets have been recently investigated to find a ...

    Abstract Introduction: The two available therapies for idiopathic pulmonary fibrosis (IPF), pirfenidone and nintedanib, slow down but do not halt IPF progression. Therefore, several agents with specific molecular targets have been recently investigated to find a cure for IPF. Phosphodiesterase 4 (PDE4) inhibition is known for its anti-inflammatory and antifibrotic properties. BI 1015550, an oral preferential inhibitor of the isoform PDE4B, could express complementary activity to current therapies in IPF and other forms of progressive pulmonary fibrosis.
    Areas covered: In this review, we first provide an overview toof the current IPF treatment market, followed by the description of pharmacokinetics and pharmacodynamics of BI 1015550. The main preclinical and early clinical evidence on BI 1015550 is then described, as well as its potential as an IPF treatment.
    Expert opinion: Oral treatment with BI 1015550 was shown to stabilize lung function as compared to placebo over 12 weeks, both among patients with and without background antifibrotic use, with an acceptable safety profile in a phase 2 trial, and a phase 3 trial has been initiated. To date, this represents to date the largest effect size for an IPF investigational drug tested in a phase 2 trial with the shortest duration.
    MeSH term(s) Humans ; Anti-Inflammatory Agents/pharmacology ; Cyclic Nucleotide Phosphodiesterases, Type 4/pharmacology ; Cyclic Nucleotide Phosphodiesterases, Type 4/therapeutic use ; Idiopathic Pulmonary Fibrosis/drug therapy ; Lung ; Phosphodiesterase Inhibitors/pharmacology ; Pyridones/adverse effects
    Chemical Substances Anti-Inflammatory Agents ; Cyclic Nucleotide Phosphodiesterases, Type 4 (EC 3.1.4.17) ; PDE4B protein, human (EC 3.1.4.17) ; Phosphodiesterase Inhibitors ; Pyridones ; BI 1015550
    Language English
    Publishing date 2023-02-03
    Publishing country England
    Document type Review ; Journal Article
    ZDB-ID 1182884-5
    ISSN 1744-7658 ; 0967-8298 ; 1354-3784
    ISSN (online) 1744-7658
    ISSN 0967-8298 ; 1354-3784
    DOI 10.1080/13543784.2023.2173061
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 3739: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article ; Online: An up-to-date review of approved and emerging antibody therapies for idiopathic pulmonary fibrosis.

    Simonetti, Jacopo / Sgalla, Giacomo / Richeldi, Luca

    Expert opinion on biological therapy

    2023  Volume 23, Issue 12, Page(s) 1239–1244

    Abstract: Introduction: The use of pirfenidone and nintedanib in treating Idiopathic Pulmonary Fibrosis (IPF) has shown significant slowing down of the progressive functional decline in these patients. In recent times, antibody-based therapies with precise ... ...

    Abstract Introduction: The use of pirfenidone and nintedanib in treating Idiopathic Pulmonary Fibrosis (IPF) has shown significant slowing down of the progressive functional decline in these patients. In recent times, antibody-based therapies with precise molecular targets have also been explored as alternative treatments to IPF.
    Areas covered: This review aims to summarize the available updates regarding monoclonal antibodies that have been tested in IPF. The drugs describedare developed to antagonize inflammation,immunity pathways and fibrogenesis. Currently, the anti-CTGF pamrevlumab has demonstrated a significant reduction in functional decline as compared to placebo and is undergoing the last stages of phase 3 trial.
    Expert opinion: Although antibody-based therapies for IPF have had unsatisfactory results in most trials in the last few years, the pursuit of therapeutic development in this field should continue to deliver a more personalized treatment approach in the future, which is currently not available with existing treatment options. However, several molecules are still under study and some have shown encouraging results in the early phases of clinical trials. Future investigations need to be more carefully designed and valid predictive markers of response to treatment should be used to enhance the effectiveness of future trials.
    MeSH term(s) Humans ; Idiopathic Pulmonary Fibrosis/drug therapy ; Pyridones/therapeutic use
    Chemical Substances Pyridones
    Language English
    Publishing date 2023-12-28
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 2052501-1
    ISSN 1744-7682 ; 1471-2598
    ISSN (online) 1744-7682
    ISSN 1471-2598
    DOI 10.1080/14712598.2023.2268014
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6094: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article ; Online: An update on emerging drugs for the treatment of idiopathic pulmonary fibrosis: a look towards 2023 and beyond.

    Sofia, Carmelo / Comes, Alessia / Sgalla, Giacomo / Richeldi, Luca

    Expert opinion on emerging drugs

    2023  Volume 28, Issue 4, Page(s) 283–296

    Abstract: Introduction: Currently approved drug treatments for idiopathic pulmonary fibrosis (IPF), pirfenidone and nintedanib, have been shown to slow lung function decline and improve clinical outcomes. Since significant advances in the understanding of ... ...

    Abstract Introduction: Currently approved drug treatments for idiopathic pulmonary fibrosis (IPF), pirfenidone and nintedanib, have been shown to slow lung function decline and improve clinical outcomes. Since significant advances in the understanding of pathogenetic mechanisms in IPF, novel potential agents are being tested to identify new targeted and better tolerated therapeutic strategies.
    Areas covered: This review describes the evidence from IPF phase II and III clinical trials that have been completed or are ongoing in recent years. The literature search was performed using Medline and Clinicaltrials.org databases. Particular attention is paid to the new inhibitor of phosphodiesterase 4B (BI 1015550), being studied in a more advanced research phase. Some emerging critical issues of the pharmacological research are highlighted considering the recent outstanding failures of several phase III trials.
    Expert opinion: An exponential number of randomized clinical trials are underway testing promising new molecules to increase treatment choices for patients with IPF and improve patients' quality of life. The next goals should aim at a deeper understanding of the pathogenic pathways of the disease with the challenging goal of being able not only to stabilize but also to reverse the ongoing fibrotic process in patients with IPF.
    MeSH term(s) Humans ; Quality of Life ; Idiopathic Pulmonary Fibrosis/drug therapy
    Chemical Substances BI 1015550
    Language English
    Publishing date 2023-12-26
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 2061369-6
    ISSN 1744-7623 ; 1472-8214
    ISSN (online) 1744-7623
    ISSN 1472-8214
    DOI 10.1080/14728214.2023.2281416
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Se 1925: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article ; Online: Targeted treatment of idiopathic pulmonary fibrosis: one step at a time.

    Richeldi, Luca

    The European respiratory journal

    2016  Volume 47, Issue 5, Page(s) 1321–1323

    Language English
    Publishing date 2016-05
    Publishing country England
    Document type Editorial
    ZDB-ID 639359-7
    ISSN 1399-3003 ; 0903-1936
    ISSN (online) 1399-3003
    ISSN 0903-1936
    DOI 10.1183/13993003.00389-2016
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2322: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 292: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top